Melanie E. Neary

Partner

mneary@gibsondunn.com

T: +1 415.393.8243

San Francisco



Melanie Neary is a partner in the San Francisco office of Gibson Dunn where she practices in the firm's Capital Markets Practice Group, focusing on representing leading life sciences companies and investors. Melanie advises clients on a wide reagrafing manager financing transactions and matters, including initial public offerings, secondary equity offerings, and venture and growth equity financings, as well as mergers and acquisitions, spin-offs, and PIPEs. Melanie regularly serves as principal outside counsel for numerous publicly-traded companies and advises management and boards of directors on corporate law matters. Securities and Exchange Commission recognition readiling mentions and Commission recognition recognition recognition recognitions and commission recognitions and commission recognition recognitions and commission recognitions are commissional recognitions. filings, and corporate governance.

Representative Clients and Transactions:

• Initial Public Offerings: Apogee Therapeutics, Rain Oncology, Shattuck Labs, Biora Therapeutics, 89bio, Cricut, Step Storie Group, Petco Health and Wellness Company, Odonate Therapeutics. Excelerate Energy

• Follow-on Equity Offerings: Apogee Therapeutics, Spyre Therapeutics, Shattuck Labs, Biora Therapeutics, Protagonist Therapeutics, Ultragenyx Pharmaceutical, 89bio, Odonate Therapeutics, Rain Oncology, Rockwell Medical, Heron Therapeutics, Rocket Pharmaceuticals, StepStone Group, Leslie's, Peloton, Eledon Pharmaceuticals, Viridian Therapeutics Education

 ATM Facilities: Protagonist Therapeutics, Shattuck Labs, Rain Oncology, Biora Therapeuticamel/tragget/ywwe/firin/iart/mageutica.cephio. Rockwell Medical, California Water Service Group, Urovant

 Debt Offerings: Mauser Packaging, California Water Service Group, Wells Fargo & Company and Wells Fargo Bank, N.A., Gran Tierra
Admissions
Admissions Energy, Keysight Technologies, Magnite

 Venture Financings: Apogee Therapeutics – Series B, Cullgen – Series C, Perceive Biotherapeutics – Series B, Ellodi Pharmaceuticals – Series B, Tourmaline Bio - Series A, Jaanuu - Series B, Waterloo Sparkling Water - Series D, Bandier - Series E, ConnectRN - Series F, Sling Therapeutics - Series B

- · Mergers and Acquisitions:
 - Cullgen in its business combination with Pulmatrix
 - Quidel in its acquisition of Ortho Clinical Diagnostics
 - Glassdoor in its sale to Recruit Holdings
 - · BPGBio in its investment in Berg, LLC
 - California Water Service Group in proposed acquisition of SJW Group
 - Novus Therapeutics in its merger transaction with Tokai Pharmaceuticals
 - · Rocket Pharmaceuticals in its merger transaction with Inotek

Melanie received her J.D. from the University of Michigan Law School in 2016, where she was the Managing Editor of the Michigan Business & Entrepreneurial Law Review. She earned her B.A., magna cum laude, in Communications, Legal Institutions, Economics and Government, with a minor in French, from American University in 2013.

Life Sciences

Media, Entertainment, and Technology Mergers and Acquisitions

2013 Bachelor of Arts